✦ LIBER ✦

Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial

✍ Scribed by Okines, A; Puerto, O del; Cunningham, D; Chau, I; Van Cutsem, E; Saltz, L; Cassidy, J

Book ID: 126646737
Publisher: Nature Publishing Group
Year: 2009
Tongue: English
Weight: 162 KB
Volume: 101
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6605259

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

FOLFIRI plus cetuximab versus FOLFIRI pl

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

✍ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 289 KB

FOLFIRI plus cetuximab versus FOLFIRI pl

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

✍ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 289 KB

FOLFIRI plus cetuximab versus FOLFIRI pl

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

✍ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 289 KB

## Background: Cetuximab and bevacizumab have both been shown to improve outcomes in patients with metastatic colorectal cancer when added to chemotherapy regimens; however, their comparative effectiveness when partnered with first-line fluorouracil, folinic acid, and irinotecan (folfiri) is unknow

Bevacizumab plus chemotherapy versus che

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

✍ von Minckwitz, Gunter; Puglisi, Fabio; Cortes, Javier; Vrdoljak, Eduard; Marschn 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 297 KB

A Phase III Randomized, Open-Label, Cont

A Phase III Randomized, Open-Label, Controlled Trial of Chemotherapy and Bevacizumab with or Without Panitumumab in the First-Line Treatment of Patients with Metastatic Colorectal Cancer

✍ Zev Wainberg; J. Randolph Hecht 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 90 KB

S-1 plus oxaliplatin versus capecitabine

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial

✍ Yong Sang Hong; Young Suk Park; Ho Yeong Lim; Jeeyun Lee; Tae Won Kim; Kyu-pyo K 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 200 KB